Homepage
Author:
Cullinan Therapeutics, Inc.
Posted Date:
June 6, 2026
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Cullinan Therapeutics, Inc.
June 6, 2026
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
Cullinan Therapeutics, Inc.
May 26, 2026
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics, Inc.
May 22, 2026
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics, Inc.
May 22, 2026
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Cullinan Therapeutics, Inc.
May 7, 2026
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cullinan Therapeutics, Inc.
March 10, 2026
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics, Inc.
February 24, 2026
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
Cullinan Therapeutics, Inc.
February 18, 2026
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
Cullinan Therapeutics, Inc.
February 8, 2026
